StocksMedium•29 September 2026•
1 min read
AbbVie Secured FDA Approval for Parkinson's Treatment Juvmo
Key Facts
1AbbVie received FDA approval for Juvmo (tavapadon) as a once-daily oral treatment for adults with Parkinson's disease.
2The new treatment is expected to be available to American patients starting in October.
3The company announced a multi-year collaboration with Iambic to utilize AI for small-molecule drug discovery.
AbbVie received FDA approval for Juvmo as a once-daily oral treatment for adults with Parkinson's disease. Kalkine Media reported that the new treatment is expected to be available to American patients starting in October. Additionally, the company announced a multi-year collaboration with Iambic to utilize artificial intelligence for small-molecule drug discovery.
ABBV closed at $266.28 on September 28, 2026, with the stock reaching a day high of $267.74 and a low of $263.38 during that session. This regulatory milestone coincides with the company's strategic move to integrate AI-driven discovery through its partnership with Iambic to accelerate future drug development.